Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future Outlook
Movement Disorders Clinical Practice · 2024-10 · 11 (10) · 1188-1194
DOI: 10.1002/mdc3.14161 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 11.07.2024. Verfasst von Mickael Aubignat und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Movement Disorders, Amiens Picardie University Hospital, Amiens, France. Hauptthemen laut MEDLINE: Parkinson Disease, Carbidopa, Levodopa, Antiparkinson Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non‐motor symptoms, primarily because of the impairment of dopaminergic neurons. Long‐term use of levodopa, the standard PD treatment, often results in fluctuating therapeutic effects and dyskinesia, necessitating alternative therapies.
Objectives
This review aims to synthesize current insights and clinical experiences with foslevodopa‐foscarbidopa, focusing on its pharmacokinetics, efficacy, and safety profile, to evaluate its potential in transforming PD therapy.
Methods
A systematic literature search was conducted up to November 2023 using databases PubMed, Web of Science, and Cochrane Library. The search yielded eight eligible articles, including pharmacological studies, case reports, observational studies, and controlled trials. No language restrictions were applied.
Results
Foslevodopa and foscarbidopa, as prodrugs of levodopa and carbidopa, exhibited excellent chemical stability and solubility, facilitating continuous subcutaneous infusion. Clinical trials demonstrated that these prodrugs maintain stable levodopa levels, thereby addressing the limitations of oral levodopa therapy. Phase 1 and 3 studies indicated significant improvements in motor function and quality of life in advanced PD patients. However, a higher incidence of treatment‐emergent adverse events, mainly infusion site reactions, was observed compared to oral therapies.
Conclusions
Foslevodopa‐foscarbidopa emerges as a promising alternative for advanced PD treatment, offering sustained symptom control. Its efficacy in managing motor fluctuations and dyskinesia makes it a viable option in the PD therapeutic spectrum. Future research should focus on long‐term safety, economic impact, and broader accessibility. Foslevodopa‐foscarbidopa is now commercially distributed in many countries in Europe and in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Movement Disorders, Amiens Picardie University Hospital, Amiens, France.
- Expert Center for Parkinson's Disease, Amiens Picardie University Hospital, Amiens, France.
ORCID-Profile: Mickael Aubignat
Zitieren
APA
Aubignat, M., & Tir, M. (2024). Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future Outlook. Movement Disorders Clinical Practice, 11(10), 1188-1194. https://doi.org/10.1002/mdc3.14161
Vancouver
Aubignat M, Tir M. Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future Outlook. Movement Disorders Clinical Practice. 2024;11(10):1188-1194. doi:10.1002/mdc3.14161
BibTeX
@article{Aubignat2024,
author = {Aubignat, Mickael and Tir, Melissa},
title = {Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future Outlook},
journal = {Movement Disorders Clinical Practice},
year = {2024},
volume = {11},
number = {10},
pages = {1188--1194},
doi = {10.1002/mdc3.14161}
}
EUVIMED